<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41024110</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1465-542X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Breast cancer research : BCR</Title><ISOAbbreviation>Breast Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.</ArticleTitle><Pagination><StartPage>171</StartPage><MedlinePgn>171</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13058-025-02108-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Inflammatory breast cancer (IBC) is an aggressive and highly angiogenic disease. Eribulin is a microtubule inhibitor with anti-angiogenic properties.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a phase II trial, we examined the efficacy of an eribulin-containing neoadjuvant regimen (eribulin-&#x2009;&gt;&#x2009;doxorubicin plus cyclophosphamide (AC) or AC-&#x2009;&gt;&#x2009;eribulin) for patients with newly diagnosed HER2-negative IBC. Pathologic complete response (pCR: ypT0/Tis ypN0) was the primary endpoint; residual cancer burden (RCB) categories were also recorded. Five patients from each cohort underwent dynamic contrast enhanced MRI (DCE-MRI) and diffusion weighted MRI. All patients had research breast biopsies for transcriptomic, differential gene expression, and cell subset analysis at baseline and one week after the first dose of therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">19/22 (86.4%) patients had hormone receptor-positive disease. All patients were able to undergo planned curative-intent surgery and radiation. One patient had a pCR, and long-term outcomes were encouraging: after median follow up of 76&#xa0;months, 3 patients experienced disease recurrence. Five-year event-free survival (EFS) was 85.6%. The regimen was tolerated with expected side effects-the most common grade 1 or 2 AEs were fatigue (95.5%), nausea (68.2%), and alopecia (63.6%). Seven out of 22 (31.8%) patients experienced any grade 3 or 4 AE, with neutropenia (22.7%) being the most common. DCE-MRI showed decreased tumor vascularization after 1&#xa0;week of treatment versus baseline. Transcriptomic analysis using quantification of synthesized dsDNA libraries and tumor microenvironment analysis of paired baseline and on-treatment samples showed residual cancer burden (RCB)-III tumors were more likely to have genes associated with adipogenesis/fatty acid metabolism and cells associated with immunosuppression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite the low pCR rate, all patients were able to undergo curative surgery, and long-term outcomes were encouraging with 5-year EFS 85.6%. Decreases in tumor vascularization with treatment were detected by DCE-MRI parameters irrespective of initial chemotherapy received. Adipogenesis/fatty acid metabolism and cells associated with immunosuppression are potential mechanisms of resistance and targets for future investigation in this unique patient population.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov (NCT02623972)(Registration date: 12/02/15).</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Fanucci</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yeh</LastName><ForeName>Eren D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ruichao</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bay</LastName><ForeName>Camden P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Takeda Pharmaceuticals, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiLullo</LastName><ForeName>Molly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Ashka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>McKenna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herbert</LastName><ForeName>Zachary T</ForeName><Initials>ZT</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Beth T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakhlis</LastName><ForeName>Faina</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellon</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerriero</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolaney</LastName><ForeName>Sara M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regan</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overmoyer</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Laere</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Oncological Research (CORE) and Integrated Personalized &amp; Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lynce</LastName><ForeName>Filipa</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6615-7076</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02623972</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Breast Cancer Res</MedlineTA><NlmUniqueID>100927353</NlmUniqueID><ISSNLinking>1465-5411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005663">Furans</NameOfSubstance></Chemical><Chemical><RegistryNumber>LR24G6354G</RegistryNumber><NameOfSubstance UI="C490954">eribulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007659">Ketones</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000095662">Polyether Polyketides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058922" MajorTopicYN="Y">Inflammatory Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="Y">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095662" MajorTopicYN="N" AutoHM="Y">Polyether Polyketides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cyclophosphamide</Keyword><Keyword MajorTopicYN="N">Doxorubicin</Keyword><Keyword MajorTopicYN="N">Eribulin</Keyword><Keyword MajorTopicYN="N">HER2-negative</Keyword><Keyword MajorTopicYN="N">Inflammatory Breast Cancer</Keyword><Keyword MajorTopicYN="N">Neoadjuvant therapy</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Standards and the Declaration of Helsinki. Institutional review board approval was obtained at Dana-Farber/Harvard Cancer Center (DF/HCC). Monitoring of trial progress and safety was reviewed twice yearly by the DF/HCC independent data safety monitoring committee (DSMC). All patients provided written informed consent prior to initiating any study treatments or procedures. This trial was registered with ClinicalTrials.gov (NCT02623972). Consent for publication: Not applicable. Competing interests: BTH reports spousal employment at Eli Lilly. JB reports serving as an educational speaker for Varian; royalties from UpToDate; and honorarium from Oncoclinicas and Physician's Education Resource. JLG reports serving as a consultant for Glaxo-Smith Kline (GSK), Codagenix, Verseau Therapeutics, Kymera, Kowa, Duke Street Bio, and Array BioPharma; and receives sponsored research support from Duke Street Bio, GSK, Array BioPharma, Merck and Eli Lilly. SMT reports serving in a consulting or advisory role for&#x202f;Novartis, Pfizer (SeaGen), Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Effector, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Johnson&amp;Johnson/Ambrx, Launch Therapeutics, Zuellig Pharma, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summitt Therapeutics,&#xa0;Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, and Olema Pharmaceuticals; research funding&#xa0;from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly,&#xa0;Novartis, Bristol Myers Squibb,&#xa0;AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, OncoPep, Daiichi Sankyo, Menarini/Stemline, and Jazz&#xa0;Pharmaceuticals; and travel support from Eli Lilly, Sanofi, Gilead, Jazz Pharmaceuticals, Pfizer&#xa0;Arvinas, Roche, Sanofi, and Olema Pharmaceuticals. MR&#xa0;reports research funding/resources (to institution) from Bayer, Biotheranostics, Bristol-Myers Squibb, Novartis, Pfizer, Roche, TerSera Therapeutics, and ETOP&#xa0;IBCSG Partners Foundation; and consulting/advisory roles or honorarium for AstraZeneca, Bristol-Myers Squibb, TerSera Therapeutics, and Tolmar&#xa0;Pharmaceuticals. BO reports clinical trial support from Eisai Pharmaceuticals and Incyte Pharmaceuticals. FL reports research funding to the institution from&#xa0;AstraZeneca, Zentalis, Ideaya, Gilead, Merck, and Incyte; and advisory/consulting roles for AstraZeneca, Pfizer, Eli Lilly, and Daiichi Sankyo. The remaining&#xa0;authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41024110</ArticleId><ArticleId IdType="doi">10.1186/s13058-025-02108-4</ArticleId><ArticleId IdType="pii">10.1186/s13058-025-02108-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/dji172</ArticleId><ArticleId IdType="pubmed">15998949</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008;26(5):786&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.15.0243</ArticleId><ArticleId IdType="pubmed">18258987</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 2004;10(23):7965&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-04-0063</ArticleId><ArticleId IdType="pubmed">15585631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002800050664</ArticleId><ArticleId IdType="pubmed">9225950</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldini E, Gardin G, Evagelista G, Prochilo T, Collecchi P, Lionetto R. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer. 2004;5(5):358&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.3816/CBC.2004.n.042</ArticleId><ArticleId IdType="pubmed">15585073</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004;4(6):415&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.3816/CBC.2004.n.004</ArticleId><ArticleId IdType="pubmed">15023242</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata Y, Uemura D. Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl Chem. 1986;58(5):701&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1351/pac198658050701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem. 1991;266(24):15882&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)98491-7</ArticleId><ArticleId IdType="pubmed">1874739</ArticleId></ArticleIdList></Reference><Reference><Citation>Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105(10):1334&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12488</ArticleId><ArticleId IdType="pubmed">25060424</ArticleId><ArticleId IdType="pmc">4462349</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes J, O&#x2019;Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, et al. Eribulin monotherapy versus treatment of physician&#x2019;s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60070-6</ArticleId><ArticleId IdType="pubmed">21376385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.50.9984</ArticleId><ArticleId IdType="pubmed">24101045</ArticleId></ArticleIdList></Reference><Reference><Citation>Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.10.6823</ArticleId><ArticleId IdType="pubmed">17785706</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, Dominici LS, Golshan M, Jacene HA, Yeh ED, et al. The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Ann Surg Oncol. 2017;24(9):2563&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-017-5903-6</ArticleId><ArticleId IdType="pubmed">28560598</ArticleId></ArticleIdList></Reference><Reference><Citation>Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17676</ArticleId><ArticleId IdType="pubmed">27135926</ArticleId><ArticleId IdType="pmc">4910866</ArticleId></ArticleIdList></Reference><Reference><Citation>Fram EK, Herfkens RJ, Johnson GA, Glover GH, Karis JP, Shimakawa A, Perkins TG, Pelc NJ. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imaging. 1987;5(3):201&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0730-725X(87)90021-X</ArticleId><ArticleId IdType="pubmed">3626789</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalifa F, Soliman A, El-Baz A, Abou El-Ghar M, El-Diasty T, Gimel&#x2019;farb G, Ouseph R, Dwyer AC. Models and methods for analyzing DCE-MRI: a review. Med Phys. 2014;41(12):124301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1118/1.4898202</ArticleId><ArticleId IdType="pubmed">25471985</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1522-2586(199909)10:3&lt;223::AID-JMRI2&gt;3.0.CO;2-S</ArticleId><ArticleId IdType="pubmed">10508281</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker GJ, Roberts C, Macdonald A, Buonaccorsi GA, Cheung S, Buckley DL, Jackson A, Watson Y, Davies K, Jayson GC. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med. 2006;56(5):993&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.21066</ArticleId><ArticleId IdType="pubmed">17036301</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusztai L, Denkert C, O&#x2019;Shaughnessy J, Cortes J, Dent R, McArthur H, K&#xfc;mmel S, Bergh J, Park YH, Hui R, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol. 2024;35(5):429&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2024.02.002</ArticleId><ArticleId IdType="pubmed">38369015</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol. 2003;21(8):1431&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2003.09.081</ArticleId><ArticleId IdType="pubmed">12668651</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol. 2014;25(2):384&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdt525</ArticleId><ArticleId IdType="pubmed">24351399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupstas AR, Hoskin TL, Day CN, Boughey JC, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 2020;107(8):1033&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.11469</ArticleId><ArticleId IdType="pubmed">32057107</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AB, Lynce F. Tailoring treatment for patients with inflammatory breast cancer. Curr Treat Options Oncol. 2023;24(6):580&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11864-023-01077-0</ArticleId><ArticleId IdType="pubmed">37043118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106(5):1000&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.21726</ArticleId><ArticleId IdType="pubmed">16444747</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, et al. Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD). J Clin Oncol. 2024;42(16_suppl):1007&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.16_suppl.1007</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy NJ, Yang X, Linnoila IR, Merino MJ, Hewitt SM, Parr AL, Paik S, Steinberg SM, Hartmann DP, Mourali N, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res. 2002;8(12):3857&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473600</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7(2):186&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/84635</ArticleId><ArticleId IdType="pubmed">11175849</ArticleId></ArticleIdList></Reference><Reference><Citation>Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B. Inflammatory breast cancer: what to know about this unique, aggressive breast cancer. Surg Clin North Am. 2018;98(4):787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suc.2018.03.009</ArticleId><ArticleId IdType="pubmed">30005774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhao L, Semba T, Song X, Knafl M, Krishnamurthy S, Shao S, Coffer LW II, Alexander A, Wood A, et al. Abstract 1395: genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer. Cancer Res. 2023;83(7_Supplement):1395&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-1395</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshi M, Tokumaru Y, Angarita FA, Lee L, Yan L, Matsuyama R, Endo I, Takabe K. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Sci Rep. 2021;11(1):12541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91897-7</ArticleId><ArticleId IdType="pubmed">34131208</ArticleId><ArticleId IdType="pmc">8206113</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Cha YJ, Koo JS. Adipocyte biology in breast cancer: from silent bystander to active facilitator. Prog Lipid Res. 2018;69:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2017.11.002</ArticleId><ArticleId IdType="pubmed">29175445</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco ME. Fatty acid metabolism in breast cancer subtypes. Oncotarget. 2017;8(17):29487&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.15494</ArticleId><ArticleId IdType="pubmed">28412757</ArticleId><ArticleId IdType="pmc">5438746</ArticleId></ArticleIdList></Reference><Reference><Citation>Marelli G, Morina N, Portale F, Pandini M, Iovino M, Di Conza G, Ho PC, Di Mitri D. Lipid-loaded macrophages as new therapeutic target in cancer. J Immunother Cancer. 2022. https://doi.org/10.1136/jitc-2022-004584 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2022-004584</ArticleId><ArticleId IdType="pubmed">35858707</ArticleId><ArticleId IdType="pmc">9305820</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, Harrison BT, Lynce F, Lin NU, Partridge A, et al. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Ther Adv Med Oncol. 2022;14:17588359221113268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17588359221113269</ArticleId><ArticleId IdType="pubmed">35923923</ArticleId><ArticleId IdType="pmc">9340890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, et al. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. Cancer Immunol Res. 2019;7(6):1025&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0619</ArticleId><ArticleId IdType="pubmed">31043414</ArticleId><ArticleId IdType="pmc">7053657</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertucci F, Lerebours F, Ceccarelli M, Guille A, Syed N, Finetti P, Adelaide J, Van Laere S, Goncalves A, Viens P, et al. Mutational landscape of inflammatory breast cancer. J Transl Med. 2024;22(1):374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-024-05198-4</ArticleId><ArticleId IdType="pubmed">38637846</ArticleId><ArticleId IdType="pmc">11025259</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Kumar S, Harmanci A, Li S, Kitchen RR, Zhang Y, Wali VB, Reddy SM, Woodward WA, Reuben JM, et al. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Genome Med. 2021;13(1):70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-021-00879-x</ArticleId><ArticleId IdType="pubmed">33902690</ArticleId><ArticleId IdType="pmc">8077918</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanta G, Bonin S. Overview on clinical relevance of intra-tumor heterogeneity. Front Med. 2018;5: 85.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>